ReviewJournal of inflammation research2025
Current Insights and Future Perspectives for the Use of Serological Biomarkers in Polymyalgia Rheumatica.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica.European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is currently no gold standard diagnostic test or validated serological biomarker to monitor disease activity or inform disease prognostication in isolated Polymyalgia Rheumatica (PMR). This presents significant challenges as the diagnosis of PMR is often complicated by multiple disease mimics, and the disease course remains highly variable, with no way to predict who will experience multiple disease relapses and high cumulative glucocorticoid burden. Furthermore, with the expansion of the therapeutic armamentarium of PMR, it is evident that our current one size fits all management strategy is no longer sufficient. In this narrative review, we summarise recent studies evaluating serological biomarkers for the diagnosis and prognostication of PMR, as well as their roles in disease activity monitoring and in identifying concomitant giant cell arteritis. We discuss their limitations, and explore barriers to their clinical translation, and finally highlight key directions for future research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.